Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Re-Injection of NX-1207 for BPH
NCT01846793Phase 3Completed
- Sponsor
- Nymox Pharmaceutical
- Start
- Apr 2013
- Primary completion
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of fexapotide triflutate in benign prostatic hyperplasia (BPH), sponsored by Nymox Pharmaceutical. Started Apr 2013; status: completed.
02
Drugs
fexapotide triflutate
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01846793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01846793.